



SYNTHESIS OF -5-(SUBSTITUTED PHENYL)-5-(SUBSTITUTED BENZYL)-2-SUBSTITUTED HYDANTION

S. V. KOLHE*, **R. E. BHADANGE**, **G. B. ANDHALE** and
A. R. SOMWANSHI

P.G. Department of Chemistry, Shri Shivaji College, AKOT, Dist. Akola (M.S.) INDIA

ABSTRACT

2-hydroxy-3-substituted acetophenone were refluxed in DMSO medium in presence of mercuric acetate to get substituted coumaran-3-ones. The resulting substituted coumaran-3-ones is refluxed with urea in alkaline medium and alcohol gives 5-(substituted phenyl)-5-(substituted benzyl)-2-substituted hydantion.

Key words: Substituted coumaran-3-one, Urea, Mercuric acetate, Substituted hydantion.

INTRODUCTION

Hydantion is an imidazole. Many of the physiologically compounds used in medicinal chemistry are imadazole derivatives.

Benzil (α -diketone) condensed with urea¹ and substituted urea^{2,3} in alkaline ethanolic medium yielded hydantion. Hydantion and its derivatives have been reported as herbicidal, fungicides⁴, antidiabetic⁵, show anti HIV activity⁶, anticonvulsant⁷, antinociceptive activity⁸.

Substituted hydantion analogs as a novel class of antitumor agents⁹, antimicrobial activity¹⁰ and anti arrhythmic activity¹¹.

EXPERIMENTAL

The melting points were taken in a capillary tube, IR spectra were recorded in Nijol, ¹H NMR spectra were recorded in CDCl₃ with TMS as an internal slandered. The purity of synthesized compounds was check by TLC. The structural elucidation of compound was done on the basis of chemical and spectral data.

* Author for correspondence; E-mail: sanjaykolhe22@yahoo.in

Preparation of 5-(2-hydroxy-3-nitro-5-chloro phenyl) 5-(α -hydroxy-4-methoxy benzyl)-2-hydantion (II a)

2-(4'-methoxy benzylidene)-5- chloro-7-nitro coumaran-3-one (I a) (0.01 mole) and urea (0.01 mole) were dissolved in 40 mL of ethanol. To this mixture 10 mL of 10% KOH was added drop wise with constant stirring, allowed to stand for 2 to 3 hours. The reaction mixture was refluxed for 3 hrs. Cooled and then diluted with ice cold water washed several time with 1% NaHCO₃ solution and then with distilled water. It was then crystallized from ethanol to get 5-(2-hydroxy-3-nitro-5-chloro phenyl) 5-(α -hydroxy-4-methoxy benzyl)-2-hydantion (II a).

The structure of compound (II a) has been supported by chemical and spectral data.

Properties of the compound (II a)

- Deep buff color crystalline solid m.p. 126°C.
- It shows positive ferric chloride indicating non-involvement of phenolic -OH group.
- An IR spectrum was recorded in Nijol.

I.	3852	(-N-H, stretching).
II.	3853	(-N-H, stretching).
III.	3815-3801	(-OH group stretching).
IV.	1705	(Lactum cyclic C=O group stretching).
V.	1511	(-NO ₂ group symmetrical aromatic stretching).
VI.	1340	(-NO ₂ group unsymmetrical aromatic stretching).
VII.	1251	(-NH bond stretching)
VIII.	1060	(-CHOH group stretching).
IX.	767 cm ⁻¹	(C-Cl group stretching).
- ¹H NMR in CDCl₃ with TMS as an internal standard.

I.	1.25	(s, 1H, -CH).
II.	3.9	(s, 3H, Ar-OCH ₃ group).
III.	6.3-6.4	(broad, 1H -OH).
IV.	6.8	(m, 6H, Ar-H).
V.	6.9-7.8 δ	(s, 1H, Ar-OH).

These chemical and spectral data shows that compound (**II a**) is get 5-(2-hydroxy-3-nitro-5-chloro phenyl) 5- (α -hydroxy-4-methoxy benzyl)-2-hydantion.

Similarly other compounds (**II b–II p**) were prepared by above method.




Table 1: Synthesized compounds, M.P.'s and yields

S. No.	Compounds	R ₁	R ₂	R ₃	R ₄	M.P. (°C)	Yield (%)
1	II a	NO ₂	OCH ₃	H	H	126	76
2	II b	NO ₂	H	H	H	155	72
3	II c	NO ₂	H	H	OH	145	83
4	II d	NO ₂	H	NO ₂	H	128	78
5	II e	H	H	H	H	109	69
6	II f	H	OCH ₃	H	H	98	82
7	II g	H	H	H	OH	129	75

Cont...

S. No.	Compounds	R ₁	R ₂	R ₃	R ₄	M.P. (°C)	Yield (%)
8	II h	H	H	NO ₂	H	105	78
9	II i	Br	H	H	H	121	84
10	II j	Br	OCH ₃	H	H	171	73
11	II k	Br	H	H	OH	286	78
12	II l	Br	H	NO ₂	H	242	76
13	II m	Cl	H	H	H	197	82
14	II n	Cl	OCH ₃	H	H	137	86
15	II o	Cl	H	H	OH	142	78
16	II p	Cl	H	NO ₂	H	124	81

REFERENCES

1. Vogel's Test Book of Organic Practical Chemistry, 5th Ed., Longman Publication, UK (1989) p. 1153.
2. W. Garry Bowness and S. Balbir et al., J. Chem. Soc. Perkin, Tran-I, (II) (Eng.), 2649-2653 (1983).
3. J. Brown Christopher and A. R. Bulter, J. Chem. Soc., Perkin, Trans-II, (Eng.), 731-740, 3567-3572 (1989).
4. Schroder, Ludwing et al., Eur. Pat. Appl. Ep., 91, Oct., (1983), DE. Appl. 3, 213140, 08, Apr., (1982), p. 47.
5. Eisiac Co. Ltd. Jpn. Kokai Tokkyo Koho Jp., 58, 213, 717, (1983), Appl. 83/6085, 20th Jan. (1982) p. 18.
6. Comber, N. Robert, Revnolds, C. Robert et al., J. Med. Chem., (Eng.) **35(19)**, 3567-3572 (1992).
7. Rydzik, Elfrada, Kaminoka Anna, Acta. Pol. Pharm., (Pol.) **41(4)**, 459-464 (1984).
8. Zhou, Zinpei et al., Zbongguo Yooke Dacue Auebao, **22(6)**, 330-333 (1991).
9. A. M. Al-Obaid, H. I. El-Subbagh and A. I. Khodair, J. Anti-Cancer Drugs, 105-110 (1996).

10. Ewa Szymanska and Katarzyna Kiec-Kononowicz, *Farmaco*, **57(1)**, 39-44 (2002).
11. Wei Zhang and Lu Yimin, *Org. Lett.*, **219**, 1015 (2010).

Revised : 09.09.2012

Accepted : 11.09.2012